Who We Are
The ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell and Gene Therapy is composed of prominent experts in the cell and gene therapy field. Their leadership spans academia, industry, and regulation. The Task Force strives to characterize unproven and unethical cell and gene interventions, and promote safe and effective practices worldwide.
Learn more about the Task Force – Click here to view
News
| November 2018 |
ISCT publishes annual report on cell and gene therapy market authorizations |
| June 2018 |
Speakers from ISCT’s 2018 Annual Meeting Presidential Task Force Session on UCTs referenced in The Medicine Maker: Peter Marks, Massimo Dominici |
| June 20, 2018 |
ISCT Presidential Task Force on UCT Committee Members publish in Lancet Respiratory Medicine: Leigh Turner, Dan Weiss, Laertis Ikonomou |
| August 30, 2017 |
ISCT Response to Aug 28th FDA Statement Concerning Regulatory Oversight of Cellular Therapies |
| August 28, 2017 |
US FDA Commissioner Scott Gottlieb, M.D., issues statement on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine |
| July 7, 2017 |
Global interest in report co-authored by members of ISCT Presidential Task Force on UCT |
| December 2, 2016 |
ISCT Publishes Article in Translational Scientist Concerning the US REGROW Act |
| October 19, 2016 |
ISCT Presidential Task Force Publishes Article in Brain Circulation Journal |
